Circio Holding ASA: Registration of share capital increase following conversion of convertible bonds

Summary by AI ^BETAClose X

Circio Holding ASA announced that the share capital increase, related to the conversion of convertible bonds by Atlas Special Opportunities, LLC, has been registered. The company's new share capital is NOK 65,305,046.40, divided into 108,841,744 shares, with each share having a nominal value of NOK 0.60. This follows the company's previous announcement on September 5, 2025, regarding the requested conversion.

Disclaimer*

Oslo, 9 September 2025: Reference is made to the stock exchange announcement by Circio Holding ASA (OSE:CRNA) (the "Company") on 5 September 2025, regarding the requested conversion of convertible bonds by Atlas Special Opportunities, LLC. The share capital increase has now been registered with the Norwegian Register of Business Enterprises (Nw. Foretaksregisteret). The Company's new share capital is NOK 65,305,046.40 divided into 108,841,744 shares, each with a nominal value of NOK 0.60.

About Circio
Building circular RNA expression systems for enhanced gene and cell therapies

Circio Holding ASA is a biotechnology company developing powerful circular RNA vector expression technology for next generation nucleic acid medicine.

Circio has established a unique circular RNA (circRNA) vector expression technology for next generation RNA, DNA and viral therapeutics. The proprietary circVec platform is based on a modular genetic cassette design for efficient biogenesis of multifunctional circRNA inside cells. The circVec platform has applications in multiple therapeutic settings, including genetic medicine, cell therapy and chronic disease. It has demonstrated over 70-fold prolonged RNA half-life and up to 15-fold enhanced protein expression vs. conventional mRNA vector systems in vivo, and has the potential to become a new gold-standard protein expression technology. The circRNA R&D activities are being conducted by the wholly owned subsidiary Circio AB in Stockholm, Sweden.

In parallel, Circio is continuing to develop its legacy immuno-oncology program, TG01, through cost-efficient external academic and industry collaborations. TG01 targets RAS-mutated cancers and is being tested in two clinical trials in Norway and the USA. TG01 is a therapeutic peptide vaccine adjuvanted by STIMULON QS-21 licensed from Agenus Inc.